Clinical trial · no report yet · Phase 3
STAR-221
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- NCT05568095 ↗
- Completed
- Arcus Biosciences, Inc.
- 23 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| YouTube | 8 | |
| Podcasts | 6 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Advanced Upper Gastrointestinal Tract Adenocarcinoma
- Interventions
- Domvanalimab; Zimberelimab; Capecitabine; Fluorouracil; Leucovorin; Oxaliplatin; Nivolumab
- Arms
- Domvanalimab + Zimberelimab + FOLFOX/CAPOX (PI Choice) · Experimental
- Nivolumab + FOLFOX/CAPOX (PI Choice) · Active comparator
- Enrollment
- 1,040
- Primary outcomes
- Overall survival
- Sponsor
- Arcus Biosciences, Inc. with Gilead Sciences, Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 21, 2022
- Primary completion
- Aug 28, 2026
- Results posted
- No
- Registry record
- NCT05568095 · updated Sep 3, 2026
Publications
linked from the registry- Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124